HIV Cancer Care Integration in Sub-Saharan Africa

By Crystal Lubbe

January 28, 2025

HIV cancer care integration

How can integrating HIV care transform cancer treatment in Africa? A recent published article explores the perspectives of healthcare providers on integrating HIV cancer care integration into cancer centers in Malawi, South Africa, Uganda, and Zimbabwe. While oncology care providers express concerns about managing patients who have both cancer and HIV, they generally maintain a positive attitude toward HIV cancer care integration. Nonetheless, several barriers, including workspace limitations, workflow disruptions, staff availability, and costs, must be addressed to optimise integrated care.

Understanding Attitudes and Barriers

Despite the challenges in clinical management, most clinicians and support staff are optimistic about integrating HIV care into cancer treatment protocols. This positive outlook is crucial for driving successful implementation. Several barriers hinder the integration of HIV and cancer care. These include workspace limitations, workflow disruptions, staff availability, and financial burdens faced by hospitals and patients alike. There is a significant need for research to clarify service delivery pathways and address systemic barriers to integrated care approaches. Understanding these pathways can facilitate smoother integration. Over 80% of respondents agree that understanding a patient’s HIV status, antiretroviral therapy (ART) status, and ART regimen would enhance the quality of cancer care. This knowledge is essential for tailoring treatment plans.

The Intersection of HIV and Cancer

Sub-Saharan Africa faces a dual burden of high HIV prevalence and a significant incidence of HIV-related cancers, such as Kaposi sarcoma, cervical cancer, and lymphoma. The region’s healthcare systems are often under-resourced, which presents considerable challenges in screening, diagnosing, and treating these cancers effectively. Integrating HIV care into cancer centers is crucial for improving patient outcomes by streamlining care and reducing barriers from separate services. Siloed healthcare negatively affects decision-making, highlighting the need for integrated models. Organisations like the National Cancer Institute (NCI) have launched programs to research HIV-associated cancers in Africa. Initiatives such as the HIV-Associated Malignancy Research Centers and the AIDS Malignancy Consortium (AMC) aim to enhance understanding and treatment strategies. These programs are vital for addressing regional healthcare needs and advancing integrated care solutions.

Economic and Health Benefits of Integration

Integrating HIV and cancer care presents significant opportunities for enhancing both economic efficiency and patient outcomes. Healthcare systems can use resources better, reducing separate pathways and minimising effort duplication. Achieving these benefits requires investment in infrastructure, training, and financial support to overcome existing barriers

Integrating care can greatly enhance life quality for patients with HIV and cancer. Therefore, tailoring cancer treatment to HIV status and ART regimen allows for personalised, effective care. This approach improves decision-making and management, leading to better survival rates and patient satisfaction.

Furthermore, there is a pressing need for policy reforms and updated clinical practice guidelines to facilitate this integration. Training programs and infrastructure improvements can address financial and operational challenges in integrated care. Such strategic reforms are crucial for a more efficient healthcare system in regions burdened by HIV and cancer.

Reference url

Recent Posts

GLP-1 Medication Access
Expanded GLP-1 Medication Access Through Formulary Updates

By HEOR Staff Writer

May 29, 2026

CVS Caremark's latest formulary changes are poised to strengthen GLP-1 Medication Access for commercial plan members by restoring coverage for select weight-management therapies. Effective October 1, 2026, Zepbound returns as a preferred option on template formularies for sponsors that elect c...
Imfinzi bladder cancer approval
Imfinzi Bladder Cancer Approval Marks Breakthrough in Immunotherapy

By HEOR Staff Writer

May 29, 2026

The Imfinzi bladder cancer approval by the FDA now offers a new immunotherapy option for adults with BCG-naïve, high-risk non-muscle-invasive bladder cancer when combined with standard BCG induction and maintenance therapy. This Imfinzi bladder cancer approval stems from the POTOMAC Phase III ...
Radioligand Therapy Prostate Cancer
Advancements in Radioligand Therapy Prostate Cancer Treatment

By HEOR Staff Writer

May 29, 2026

Radioligand Therapy Prostate Cancer has emerged as a breakthrough approach in prostate cancer treatment by linking a cancer-targeting molecule to a radioactive payload that delivers radiation directly to tumor cells. This method minimizes damage to nearby healthy tissue while demonstrating clinic...